The Alliance for Regenerative Medicine (ARM) applauds the bipartisan effort by Representatives Guthrie (R-KY), Eshoo (D-CA), Joyce (R-PA), Auchincloss (D-MA), Miller-Meeks (R-IA), and Peters (D-CA) for introducing H.R. 2666, the “Medicaid VBPs for Patients (MVP)” Act. Advancing value-based payment arrangements for cell and gene therapy has been a long-standing priority for ARM, and we view this as a step in the right direction to promoting access to cell and gene therapies for the Medicaid patients that need them.
We look forward to continuing our work with the bill sponsors, and their colleagues in the Senate, to improve the value-based payment landscape through meaningful legislative reform that supports patient access to transformative cell and gene therapies.
